Integra LifeSciences Holdings (IART) 2014年年度报告「NASDAQ」.pdf

1、INTEGRA LIMITS UNCERTAINTYFor InvestorsFor HospitalsFor SurgeonsFor Patients2014 Annual ReportTotal RevenuesSelected Financial Data:2014 Revenues by Geographic AreaUnited StatesEuropeRest of World2014 Revenues by SegmentSegment%of Total Revenues Key Product Areas 2014 RevenuesU.S.NeurosurgeryU.S.Ins

2、trumentsU.S.ExtremitiesU.S.Spine&OtherInternational26%17%15%19%23%Regenerative solutions for dural repair;tissue ablation,cranial positioning,neuro critical careSpecialty hand-held surgical instruments for the hospital and offi ce-based sett ings;surgical headlights,retractorsRegenerative solutions

3、for nerve,tendon,skin and wound;fi xation and joint replacement in small bone orthopedicsSpinal fusion hardware;orthobiologics;private label*Select product lines from each of Neurosurgery,Instruments,Extremities and Spine$245 Million$158 Million$143 Million$171 Million$211 MillionAbout IntegraRegion

4、2014 Revenues$714 Million$106 Million$108 MillionOperating Cash FlowDiluted Earnings Per ShareIn 2012,we generated$59.1 million in cash fl ows from operations,which was reduced by a$29.8 million tax withholding payment in connection with the release of certain deferred stock units and$30.6 million o

5、f accreted interest paid at the maturity of our 2012 Senior Convertible Note.*Revised for accounting principle change for the medical device excise tax.*Integra LifeSciences,a world leader in medical technology,is dedicated to limiting uncertainty for caregivers,so they can concentrate on providing

6、the best patient care.Founded in 1989 and headquartered in Plainsboro,NJ Employs approximately 3,400 employees worldwide Traded on NASDAQ under IARTIntegra strives to grow profi tably through the Execute,Optimize and Accelerate Growth strategy,off ering innovative solutions,including leading regener